The National Institute for Health and Care Excellence (NICE) have announced draft guidelines recommending Gilead’s Harvoni for regulatory approval. If approved, the combination therapy (ledipasvir-sofosbuvir) will be available to treat NHS patients with hepatitis C in England and Wales. Specifically, the drug has been recommended for the treatment of adults with genotype 1 or 4
European regulators have granted regulatory approval to Gilead Sciences’ hepatitis C combination treatment, Harvoni. Harvoni combines Gilead’s Sovaldi (sofosbuvir), a nucleotide analogue polymerase inhibitor, with NS5A inhibitor, ledipasvir, for HCV genotype 1 and 4 infection. The approval from the European Commission comes a month after the US FDA granted approval for the drug. The approval
Dow Jones reported yesterday that Gilead Sciences have dropped the diuretic cicletanine after it failed to meet targets in a mid-stage clinical trial analysing the drug’s potential in high blood pressure. The Phase II, randomised, double-blind, placebo-controlled, multicenter, dose- ranging study was evaluating the efficacy, safety and tolerability of cicletanine in comparison to a placebo
German corporation, Boehringer Ingelheim, and the Californian firm, Gilead Sciences, have entered into a licensing agreement, under which Boehringer Ingelheim has given Gilead exclusive worldwide rights for the research, development and commercialisation of its novel non-catalytic site integrase inhibitors for HIV. This includes the lead compound BI 224436, which has been evaluated in a Phase
